{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000041","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.306715+00:00","generated_at":"2026-06-24T02:38:42.796422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amphastar Q2 2022 net revenue up 21.5% YoY to $123.5M; GAAP EPS $0.33","bullets":["Net revenues $123.5M for Q2 2022, up from $101.7M in Q2 2021 (21.5% increase).","GAAP net income $17.3M ($0.33 diluted EPS) vs $7.8M ($0.16) in Q2 2021.","Adjusted non-GAAP net income $20.7M ($0.39 diluted EPS) vs $10.6M ($0.21) in Q2 2021.","CEO cites strong sales momentum; expects continued growth from ganirelix and vasopressin launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000041","json":"https://secwatch.observer/filing/0001297184-22-000041.json","markdown":"https://secwatch.observer/filing/0001297184-22-000041.md","text":"https://secwatch.observer/filing/0001297184-22-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/0001297184-22-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000041/amph-20220808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:38:42.796422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}